FDA Panel Clears Merck Insomnia Drug At Lower Dose

Law360, New York (May 22, 2013, 7:50 PM EDT) -- A U.S. Food and Drug Administration advisory panel on Wednesday recommended the regulator approve Merck & Co. Inc.’s proposed insomnia drug suvorexant, but only at the lower of two suggested dosages, finding the drug was unsafe at a higher dose.

The recommendation, which is nonbinding, came at a public meeting of the FDA's peripheral and central nervous system drugs advisory committee, a 17-member panel made up of a number of outside medical experts. The panel, with an abstention, voted 12-4 that the drug was effective in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.